Design of novel melanocortin receptor ligands: Multiple receptors, complex pharmacology, the challenge

European Journal of Pharmacology

Volumn 660, Issue 1, 2011, Pages 88-93

  Hruby, Victor J ^a   Cai, Minying ^a   Cain, James ^a   Nyberg, Joel ^a   Trivedi, Dev ^a  

^a University of Arizona   (United States)

Author keywords

Agonists and antagonists for MCR; Melanocortin receptor ligand SAR; Melanocortin receptor selective ligand; Orthosteric and allosteric ligand; Selective ligand for MCR

Indexed keywords

AFAMELANOTIDE; ALPHA INTERMEDIN; GAMMA INTERMEDIN; MELANOCORTIN RECEPTOR; MELANOCORTIN RECEPTOR AGONIST; MELANOTAN II; N ACETYL ALPHA INTERMEDIN[4-10]CYCLO[4 NORLEUCINE 5 ASPARTIC ACID 7 [3 (2 NAPHTHYL)ALANINE] 10 LYSINAMIDE];

BINDING AFFINITY; BLOOD BRAIN BARRIER; CONTROLLED STUDY; CYCLIZATION; DRUG ACTIVITY; DRUG CONFORMATION; DRUG DEGRADATION; DRUG DESIGN; DRUG POTENCY; DRUG STRUCTURE; HUMAN; HUMAN CELL; OXIDATION; PEPTIDE SYNTHESIS; PHARMACOPHORE; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION;

ALPHA-MSH; AMINO ACID SEQUENCE; ANIMALS; DRUG DESIGN; HEK293 CELLS; HUMANS; LIGANDS; MOLECULAR SEQUENCE DATA; RECEPTORS, MELANOCORTIN; SMALL MOLECULE LIBRARIES; SUBSTRATE SPECIFICITY;

EID: 79955941240     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.10.109     Document Type: Review

References (36)

1. Al-Obeidi, F., Hadley, M.E., Pettitt, B.M., Hruby, V.J., 1989a. Design of a new class of superpotent cyclic α-melanotropins based on quenched dynamic simulations. J. Amer. Chem. Soc. 111, 3413-3416.
2. Al-Obeidi, F., de Lauro Castrucci, A.-M., Hadley, M.E., Hruby, V.J., 1989b. Potent and prolonged acting cyclic lactam analogues of α-melanotropin: design based on molecular dynamics. J. Med. Chem. 32, 2555-2561.
3. Ballet, S., Mayorov, A.V., Cai, M., Tymecka, D., Chandler, K.B., Palmer, E.S., Van Rompaey, K., Misicka, A., Tourwe, D., Hruby, V.J., 2007. Novel selective human melanocortin-3 receptor ligands: use of the 4-amino-1, 2, 4, 5-tetrahydro-2-benzazepin-3-one (aba) scaffold. Bioorg. Med. Chem. Lett. 17, 2492-2498.
4. Balse-Srinivasan, P.M., Grieco, P., Cai, M., Trivedi, D., Hruby, V.J., 2003a. Structure-activity relationships of γ-MSH analogues at the human melanocortin MC3, MC4, and MC5 receptors: discovery of highly selective hMC3R, hMC4R and hMC5R analogues. J. Med. Chem. 46, 4965-4973.
5. Balse-Srinivasan, P.M., Grieco, P., Cai, M., Trivedi, D., Hruby, V.J., 2003b. Structure-activity relationships of novel cyclic α-MSH/β-MSH hybrid analogues that lead to potent and selective ligands for the human MC3R and human MC5R. J. Med. Chem. 46, 3728-3733.
6. Biron, E., Kessler, H., 2005. Convenient synthesis of N-methylammino acids compatible with solid-phase peptide synthesis. J. Org. Chem. 70, 5183-5189.
7. Cai, M., Cai, C., Mayorov, A.V., Xiong, C., Cabello, C.M., Soloshonok, V.A., Swift, J.R., Trivedi, D., Hruby, V.J., 2004a. Biological and conformational study of β-substituted prolines in MT-II template: steric effects leading to human MC5 receptor selectivity. J. Pept. Res. 63, 116-131.
8. Cai, M., Stankova, M., Pond, S.J.K., Mayorov, A.V., Perry, J.W., Yamamura, H.I., Trivedi, D., Hruby, V.J., 2004b. Real time differentiation of g-protein coupled receptor (GPCR) agonist and antagonist by two photon fluorescence laser microscopy. J. Am. Chem. Soc. 126, 7160-7161.
9. Cai, M., Mayorov, A.V., Cabello, C., Stankova, M., Trivedi, D., Hruby, V.J., 2005a. Novel 3D pharmacophore of α-MSH/γ-MSH hybrids leads to selective human MC1R and MC3R analogues. J. Med. Chem. 48, 1839-1848.
10. Cai, M., Mayorov, A.V., Ying, J., Stankova, M., Trivedi, D., Cabello, C., Hruby, V.J., 2005b. Design of novel melanotropin agonists and antagonists with high potency and selectivity for human melanocortin receptors. Peptides 26, 1481-1485. (Pubitemid 41021484)
11. Cain, J.P., Mayorov, A.V., Cai, M., Wang, H., Tan, B., Chandler, K., Lee, Y.S., Petrov, R.R., Trivedi, D., Hruby, V.J., 2006. Design, synthesis, and biological evaluation of a new class of small molecule peptide mimetics targeting the melanocortin receptors. Bioorg. Med. Chem. Letts. 16, 5462-5467.
12. Cone, R.D. (Ed.), 2000. The Melanocortin Receptors. Human Press, Totowa, NJ, pp. 1-551.
13. Doedens, L., Opperer, F., Cai, M., Beck, J.G., Dedek, M., Palmer, E., Hruby, V.J., Kessler, H., 2010. Multiple N-methylation of MT-II backbone amide bonds leads to melanocortin receptor subtype hMC1R selectivity: pharmacology and conformational studies. J. Am. Chem. Soc. 132, 8115-8128.
14. Dorr, R.T., Lines, R., Levine, N., Brooks, C., Xiang, L., Hruby, V.J., Hadley, M.E., 1996. Evaluation of melanotan ii, a superpotent cyclic melanotropic peptide in a pilot phase-1 clinical study. Life Sci. 58, 1777-1784. (Pubitemid 26148611)
15. Grieco, P., Balse, P.M., Weinberg, D., MacNeil, T., Hruby, V.J., 2000. D-amino acid scan of γ-melanocyte-stimulating hormone: importance of Trp8 on human MC3 receptor selectivity. J. Med. Chem. 43, 4998-5002.
16. Grieco, P., Cai, M., Mayorov, A.V., Trivedi, D., Hruby, V.J., 2006. Structure-activity studies of new melanocortin peptides containing an aromatic amino acid at the N-terminal position. Peptides 27, 472-481. (Pubitemid 43162919)
17. Hadley, M.E., 1988. The Melanotropic Peptides, Vols. I, II, & III. CRC Press, Inc, Boca Raton, FL.
18. Hadley, M.E., Hruby, V.J., Sharma, S.D., Dorr, R.T., Levine, N., 1993. Melanotropic peptides for therapeutic and cosmetic tanning of human skin. Ann. NY Acad. Sci. 680, 424-439.
19. Hruby, V.J., 1982. Conformational restrictions of biologically active peptides via amino acid side chain groups. Life Sci. 31, 189-199. (Pubitemid 12026247)
20. Hruby, V.J., Wilkes, B.C., Hadley, M.E., Al-Obeidi, F., Sawyer, T.K., Staples, D.J., de Vaux, A.E., Dym, O., de Lauro Castrucci, A.-M., Hintz, M.F., Riehm, J.R., Rao, R.R., 1987. α-Melanotropin: theminimumactive sequence in the frog skin bioassay. J. Med. Chem. 30, 2126-2130.
21. Hruby, V.J., Al-Obeidi, F., Kazmierski, W.M., 1990. Emerging approaches in the molecular design of receptor selective peptide ligands: conformational, topographical and dynamic considerations. Biochem. J 268, 249-262. (Pubitemid 20193959)
22. Hruby, V.J., Sharma, S.D., Collins, N., Matsunaga, T.O., Russell, K.C., 1992. Applications of synthetic peptides to biological and medical research. In: Grant, G.A. (Ed.), Synthetic Peptides: a User's Guide. W. H. Freeman and Company, New York, pp. 259-345.
23. Hruby, V.J., Qian, X., 1994. Approaches to the asymmetric synthesis of unusual amino acids methods in molecular biology. In: Pennington, M.W., Dunn, B.M. (Eds.), Peptide Synthesis and Purification Protocols, vol. 35. Humana Press Inc., Clifton, NJ, pp. 249-286.
24. Hruby, V.J., Li, G., Haskell-Luevano, C., Shenderovich, M.D., 1997. Design of peptides, proteins, and peptidomimetics in chi space. Biopolym. Pept. Sci. 43, 219-266.
25. Hruby, V.J., Meyer, J.-P., Hecht, S.M., 1998.Chemical synthesis of peptides Bioorganic Chemistry. Peptides and Proteins. Oxford Ed. University Press, NY, 27-64.
26. Hruby, V.J., 2001. Design in topographical space of peptide and peptidomimetic ligands that affect behavior. A chemist's glimpse at the mind-body problem. Acc. Chem. Res. 34, 389-397.
27. Hruby, V.J., 2002. Designing peptide receptor agonists and antagonists. Nat. Rev. Drug Discov. 1, 847-858.
28. Hruby, V.J., 2009. Organic chemistry and biology: chemical biology through the eyes of collaboration. J. Org. Chem. 74, 9245-9264.
29. Juni, A., Cai, M., Stankova, M., Waxman, A.R., Arout, C., Klein, G., Dahan, A., Hruby, V.J., Mogil, J.S., Kest, B., 2010. Sex-Specific mediation of opioid-induced hyperalgesia by the melanocortin-1 receptor. Anesthesiology 112, 181-188.
30. Sawyer, T.K., Sanfilippo, P.J., Hruby, V.J., Engel, M.H., Heward, C.B., Burnett, J.B., Hadley, M.E., 1980. [Nle4, D-Phe7]-α-Melanocyte stimulating hormone: a highly potent α-melanotropin with ultralong biological activity. Proc. Natl. Acad. Sci. U. S. A. 77, 5754-5758.
31. Sawyer, T.K., Hruby, V.J., Darman, P.S., Hadley, M.E., 1982. [4-Half-Cystine, 10-Half-Cystine]-α-melanocyte stimulating hormone: a cyclic α-melanotropin exhibiting superagonist biological activity. Proc. Natl. Acad. Sci. U. S. A. 79, 1751-1755.
32. Sawyer, T.K., de Lauro Castrucci, A.-M., Marwan, M., Staples, D.J., Affholter, J.A., DeVaux, A.E., Hruby, V.J., Hadley, M.E., 1993. Structure-activity relationships of [Nle4, D-Phe7]α-MSH: discovery of a tripeptidyl agonist exhibiting sustained bioactivity. Ann. NY Acad. Sci. 680, 597-599.
33. Vaudry, H., Eberle, A.N., 1993. The Melanotropic Peptides: Ann. N.Y. Acad. Sci., vol. 680 (687 pp.).
34. Wessells, H., Fuciarelli, K., Hansen, J., Hadley, M.E., Hruby, V.J., Dorr, R., Levine, N., 1998. Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study. J. Urol. 160, 389-393. (Pubitemid 29476684)
35. Ying, J., Kövér, K.E., Gu, X., Han, G., Trivedi, D.B., Kavarana, M.J., Hruby, V.J., 2003. Solution structures of cyclic melanocortin agonists and antagonists by NMR. Biopolym. Pept. Sci. 71, 696-716.
36. Ying, J., Gu, X., Cai, M., Dedek, M., Vagner, J., Trivedi, D., Hruby, V.J., 2006. Design, synthesis, and biological evaluation of new cyclic melanotropin peptide analogues highly selective for the human melanocortin-4 receptor. J. Med. Chem. 49, 6888-6896.